Sugi Predict

Sugi Predict / Compounds / SCHEMBL4355684

SCHEMBL4355684

SCHEMBL4355684

CCOC(=O)c1c(N)ncn1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ ALDH1A1 P00352 9/20 0.43
▸ KDM4E B2RXH2 6/20 0.43
▸ HSD17B10 Q99714 5/20 0.43
▸ HPGD P15428 4/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ MAPT P10636 3/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ TP53 P04637 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ GAA P10253 2/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ APOBEC3A P31941 1/20 0.41
▸ APOBEC3G Q9HC16 1/20 0.41
▸ MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9543561 0.84 LMNA (0.40) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL5937208 0.83 ALDH1A1 (0.47) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL28567653 0.82 LMNA (0.45) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL8352120 0.81 APOBEC3A (0.50) CYP1A2ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL22697032 0.80 MAPK1 (0.43) ALDH1A1KDM4EHSD17B10HPGDRAB9A
SCHEMBL14710629 0.80 KMT2A (0.42) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL841349 0.80 CYP1A2 (0.42) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL14567576 0.78 ALDH1A1 (0.42) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL278381 0.77 GRK6 (0.42) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL31756865 0.77 POLB (0.50) LMNACYP1A2CYP3A4MAOAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121248513-A Intermediate for synthesizing 7-methylxanthine as well as synthesis method and application thereof 河北科技大学 2026-01-02 — — CN disclosed
WO-2025245472-A1 COMPOUNDS AND RELATED METHODS USEFUL FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES REMIX THERAPEUTICS INC. (US) 2025-11-27 — — WO disclosed
US-20250340546-A1 HSD17B13 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-11-06 — — US disclosed
WO-2025085848-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-04-24 — — WO disclosed
CN-119317627-A HSD17B13 inhibitors 勃林格殷格翰国际有限公司 2025-01-14 — — CN disclosed
WO-2023237504-A1 HSD17B13 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-12-14 — — WO disclosed
WO-2023237504-A1 HSD17B13 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-12-14 — — WO disclosed
US-11666577-B2 MLKL inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-06-06 — — US disclosed
US-11666577-B2 MLKL inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-06-06 — — US disclosed
US-11666577-B2 MLKL inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-06-06 — — US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 — — US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 — — US disclosed
US-20140329871-A1 SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2014-11-06 — — US disclosed
WO-2013085824-A1 SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2013-06-13 — — WO disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 — — US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 — — US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 — — WO disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 — — US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 — — WO disclosed
US-5326776-A Tetrazoles ABBOTT LABORATORIES (US) 1994-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340546-A1 HSD17B13 INHIBITORS HSD17B3, HSD17B13, HSD17B1 LMNA 3138/4885CYP1A2 53/4885CYP3A4 68/4885
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 LMNA 701/4885CYP1A2 4548/4885CYP3A4 4748/4885
US-20140329871-A1 SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF MMP1, COL1A1, COL2A1 LMNA 1739/4885CYP1A2 2213/4885CYP3A4 3895/4885
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 LMNA 4082/4885CYP1A2 2694/4885CYP3A4 2487/4885
US-11666577-B2 MLKL inhibitors MLKL, CMKLR1, PCSK9 LMNA 577/4885CYP1A2 4629/4885CYP3A4 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.